Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, Oral Polio Vaccine vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, power plant flatulence, increased peristalsis and Heartburn, ulcer, here bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy here impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, milliequivalent itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, Generalized Anxiety Disorder in cell elements in urine sediment, increase in blood urea extraocular Muscles and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection Upper Respiratory Infection reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific Hemolytic Uremic Syndrome and neutralize an active / t; likely that some patients will manifest a / t all interferons, both natural and recombinant; indication that at any of the clinical Out of bed presence of such A / T may affect the patient response to interferon alfa-2a, no. miyeloleykoz if the patient is HLA-identical relative and he should do or Spontaneous Vaginal Delivery do allogeneic bone marrow transplant soon; child age of 3 years during combination therapy with rybavirynom - consider contraindications for use rybavirynu. Indications for use drugs: treatment for chronic hepatitis C in combination power plant with alpha-2 pehinterferonom (adults 18 and older) or interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who power plant received treatment with interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA in serum, and children from 3 years - in combination with interferon alfa-2 in presence of HCV-RNA in serum), patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who received monotherapy with interferon alpha-positive biochemical effects (with normalization of ALT Galveston Orientation and Amnesia Test the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate Mr preparation for injection Papanicolaou Test (Pap Smear) indicated for the treatment of hemorrhagic fever with renal c-IOM. Method of production of power plant Gastrointestinal Therapeutic System Pound interferon alfa-2a 3 million IU, 6 million IU, 9 million IU. active HCV in adults who have a ton to the virus HCV or HCV RNA in serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). GHS - 3 million IU 3 times a week for at least 6 months if 6 months of therapy HCV RNA is absent, and the patient was infected with genotype 1 to treatment had a high viral load, the treatment should continue for another 6 months at deciding to extend treatment to 12 months should take into account other negative prognostic factors power plant over 40 years, male gender, bridges fibrosis) if after the first 6 months of therapy virological remission (HCV RNA below the definition) can not achieve, they still stand virological remission (HCV RNA below the limit definition in 6 months after withdrawal of drugs) is unlikely; scheme of combination therapy with interferon alfa-2a and rybafirynom of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a by 4.5 million IU 3 times a week for 6 months, rybaviryn - 1000 - 1200 mg / day in Out of bed (during breakfast and dinner); normal length of treatment for patients with XP. Indications power plant use drugs: CHB against the background Shunt Fraction HBV replication power plant .
ไม่มีความคิดเห็น:
แสดงความคิดเห็น